RT Journal Article
SR Electronic
T1 Mass drug administration coverage and determinants of drug uptake for elimination of Onchocerciasis in Ulanga District
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.16.24307467
DO 10.1101/2024.05.16.24307467
A1 Mhiche, Ambakisye
A1 Gasarasi, Dinah
A1 Kabona, George
A1 Hussein, Ally
A1 Abade, Ahmed Mohamed
YR 2024
UL http://medrxiv.org/content/early/2024/05/17/2024.05.16.24307467.abstract
AB Background Onchocerciasis remain to be an important public health problem targeted for elimination in Tanzania. Ulanga District was known for its high endemicity since 1960s and has been implementing MDA through Community Directed Treatment with Ivermectin (CDTI) strategy since 1998. However, current reports indicate high prevalence of Onchocerciasis in both human and vector species probably because of poor treatment coverage indicating limited evidence for transmission. This study was conducted to assess treatment coverage and explore determinants of drug uptake during MDA program.Methods A cross-sectional community-based study using multistage cluster sampling was carried out in Ulanga District, Morogoro Tanzania from April-June 2019. Study participants were randomly selected from households and interviewed using a structured questionnaire. Modified Poisson regression was performed to determine independent factors associated with MDA uptake.Results A total of 502 participants were recruited during the study period with a response rate of 96%. The majority (67%) were females, and the mean age of the study participants was 37.8 ±15 years with an age range of 25–34 (25.5 %). MDA coverage for the studied villages was as follows; Mawasiliano (68%) Uponera (83%), Isongo (84%) and Togo (79%). The drug uptake for all villages was below the optimal coverage recommended by WHO (85%) for successful transmission interruption. Having an age of ≤ 24 years [Adjusted Prevalence Ration (APR) = 3.9(95% CI:1.9-8.3), p < 0.05)], Living in the village for at least a year [APR = 3.4 (95% CI:2.4-4.8), p <0.05)] and believing IVM prevent Onchocerciasis [APR = 13.4(95% CI:2.9-60.9)], p<0.05) were associated with increased chances of Ivermectin uptake during MDA. In addition, decreased drug uptake [APR = 12(95% CI: 2.4-60.9), p<0.05)] was attributable to fear of restriction to drinking alcohol after taking drugs.Conclusion Low coverage below the WHO optimal recommended coverage has been demonstrated in the studied villages. This implies low drug uptake, delayed interruption of transmission and Onchocerciasis elimination. These findings, therefore, emphasize the need to intensify the MDA awareness campaigns targeting less compliant groups in the community to reinforce the benefits of ivermectin in Onchocerciasis control and address the community misconceptions about MDA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Muhimbili University of Health and Allied Science ethical review boardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe fully consent that data used in this study will be made available.